• Publications
  • Influence
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer
Triple-negative breast cancers (TNBCs) have poor prognosis and lack targeted therapies. Here we identified increased copy number and expression of the PIM1 proto-oncogene in genomic data sets ofExpand
  • 96
  • 7
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Purpose: AZD5363/capivasertib is a pan-AKT catalytic inhibitor with promising activity in combination with paclitaxel in triple-negative metastatic breast cancer harboring PI3K/AKT-pathwayExpand
  • 1
  • 1
Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer
Triple negative breast cancers (TNBCs) lack recurrent targetable driver mutations but demonstrate frequent copy number aberrations (CNAs). Here, we describe an integrative genomic and RNAi-basedExpand
  • 22
  • PDF
PIM 1 kinase regulates cell death , tumor growth and chemotherapy response in triple-negative breast cancer
Triple-negative breast cancers (TNBCs) have poor prognosis and lack targeted therapies. Here we identified increased copy number and expression of the PIM1 proto-oncogene in genomic data sets ofExpand
  • 4
  • PDF
Erratum: PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer
Constanze Schneider, Thomas Oellerich, Hanna-Mari Baldauf, Sarah-Marie Schwarz, Dominique Thomas, Robert Flick, Hanibal Bohnenberger, Lars Kaderali, Lena Stegmann, Anjali Cremer, Margarethe Martin,Expand
  • 1
Abstract 178: PIM1, a novel target in chemotherapy-resistant triple-negative breast cancer
Triple-Negative Breast Cancers (TNBCs) are aggressive, associated with poor prognosis and lack targeted therapies, mainly due to the absence of suitable molecular targets. The genomic region 6p21-p25Expand
ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC).
UK Breast Cancer Research Symposium 2016: Submitted Abstracts
UK Breast Cancer Research Symposium 2016: Submitted Abstracts The Author(s) 2016. This article is published with open access at Springerlink.com Breast cancer risk alleles in separate gene regulatoryExpand